Bill > SB875

This bill establishes the Medetomidine and Xylazine Consumer Protection Act, which creates strict regulations around the sale of products containing medetomidine and xylazine, two substances with potential for misuse. The bill requires retailers (defined broadly to include manufacturers, online platforms, and other business entities) to obtain proof from purchasers that the products will be used for legitimate institutional, veterinary, or scientific purposes, and prohibits selling these products to individuals under 21 years old. Retailers must maintain detailed records of sales, including identification used to verify age and documentation of intended use. Violations of these regulations are subject to civil penalties, with first-time offenders facing up to $3,000 in fines and subsequent violations incurring up to $6,500 in penalties. All collected civil penalties will be remitted to the Comptroller and deposited in the Maryland Substance Abuse Fund. The law is set to take effect on October 1, 2025, and the state's Department of Health is tasked with adopting regulations to implement the new requirements. The bill appears aimed at preventing potential misuse of these substances, which may have harmful effects when used improperly.

Budget and Finance

https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/SB0875?ys=2025RS